Compare State Street SPDR S&P Biotech ETF (XBI) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Health Care Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $154.38, while Health Care Select Sector SPDR Fund trades at $160.11. Which is the better fit depends on your goals.
| XBI | XLV | |
|---|---|---|
Sector | Broad Market / Factor | — |
52-Week High | $164.28 | $164.48 |
52-Week Low | $85.16 | $129.01 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.
XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
